Prostate cancer is a significant and increasing health problem worldwide and is a leading cause of male cancer deaths.1
Docetaxel is a widely approved drug, also with proven activity in both early and late stage prostate cancer.2
Oasmia’s docetaxel micellar formulation improves the solubility of docetaxel and so avoid the mandatory use of steroid pre-medication which is considered detrimental in advanced stage patients with active cancer in the bone.
1 Ref Rawla, P. World J Oncol. 2019 Apr; 10(2): 63–89.